Triage of Developmental and Reproductive Toxicants using IVIVE-Toxicokinetic Modeling
Official title: Triage of Developmental and Reproductive Toxicants using an In vitro to In Vivo Extrapolation (IVIVE)-Toxicokinetic Computational modeling Application
Funded at Scitovation, LLC · NIH-11332946 · Data updated 2026-11-12
A research team is building a web tool that translates lab test results into human-safe exposure levels to better protect developing babies from chemicals, without animal testing.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scitovation, LLC NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 7, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $983,133 |
| NIH project number | 5R44ES035657-03 |
| Project ID | NIH-11332946 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable in this stage, as the grant is focused on tool development and computational modeling rather than enrolling patients.
✕Less likely to help
There are no direct patient participants required for this phase of the project.
What this research studies
This project extends a technology called DRIIVE that links in vitro findings to what people might experience in real life. It uses a three-tier PBPK model to estimate human equivalent exposure levels from lab observations, helping researchers and regulators assess developmental toxicity more safely. The effort includes creating a user-friendly web interface so scientists can apply these calculations to drugs or chemicals. By focusing on developmental and reproductive safety, the work aims to reduce animal testing while maintaining confidence in human risk assessments.
Why it matters
Potential benefit: If successful, the tool could streamline safer chemical and drug development and improve public health protections for pregnant people and developing fetuses.
How similar studies have gone: Previous work showed that IVIVE-PBPK approaches can improve translation from lab to human exposure predictions, with ongoing development of NAMs.
Where this research is happening
-
Scitovation, LLC
Durham, United States Active
Researchers
- Principal investigator: Antonijevic, Todor — Scitovation, LLC
- Study coordinator: Antonijevic, Todor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.